Drug
Chf6563
Chf6563: highest development phase Phase 2, developed by Chiesi Farmaceutici. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Chiesi Farmaceutici
Trials
| Drug | Phase | Indication |
|---|---|---|
| CHF6563 NCT04104646 | Phase 2 | Neonatal Opioid Withdrawal Syndrome |
Latest
No recent events.
Follow Chf6563 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.